Roche in Cancer Care

The Roche Group is the world's leading provider of cancer care products. Our anti-cancer medicines are saving lives and significantly advancing the way some cancers are treated. The Roche portfolio currently includes five innovative cancer products proven to provide survival benefit in a number of different tumor types: Avastin® (bevacizumab), Herceptin® (trastuzumab), Xeloda® (capecitabine), MabThera® (rituximab) and Tarceva® (erlotinib).

In addition, Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future. With a broad portfolio of tumour markers as well as a range of molecular oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics.

Attached media for this topic

About oncology
About Roche in oncologyPDF
Roche Oncology R&DPDF
Personalized Healthcare in OncologyPDF
Epidemiology of cancerPDF
Specific indications
Breast cancer PDF
Stomach cancer PDF
Chronic Lymphocytic LeukemiaPDF
Colorectal cancer PDF
Non-Hodgkin's Lymphoma PDF
Non Small Cell Lung cancer PDF
HER2-positive cancerPDF
Skin cancer (Melanoma) PDF
Ovarian cancerPDF
Advanced Basal Cell CarcinomaPDF
Cervical cancer PDF
Info graphic
Cervical cancerPDF
Lung cancerPDF
Stages of Breast cancerPDF
Colorectal cancerPDF
Non Hodgkins LymphomaPDF
Chronic lymphocytic leukemiaPDF
Advanced Basal Cell CarcinomaPDF
Avastin ProductionZIP